Abstract
Three new ruthenium(II) complexes with biphenyl (bip), and disubstituted 1,2,4-triazolo[1,5-a]pyrimidine (dstp) of the general formula [(η6-bip)Ru(dstp)Cl2], where dstp – dmtp–5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidine for (1), dptp–5,7-diphenyl-1,2,4-triazolo[1,5-a]pyrimidine for (2), or ibmtp–7-isobutyl-5-methyl-1,2,4-triazolo[1,5-a]pyrimidine for (3) have been synthesized and fully characterized by an elemental analysis and spectroscopic methods (1H, 13C, 15N NMR; IR; X–ray). The crystal sructures of two complexes have been solved. To determine the therapeutic potential of the newly synthesized compounds, examinations of their biological properties such as lipophilicity and in vitro cytotoxicity towards T47D (breast cancer), A549 (non-small cell lung cancer), LoVo (colon cancer), and one healthy cell line mouse fibroblasts–BALB3T3 were preformed. The results show that all the tested ruthenium(II) complexes present higher lipophilicity (logP = 0.79–1.43) than Cisplatin (−2.31). From among all the newly obtained complexes,(2)(IC50 = 25 – 29 µM) exhibits the highest cytotoxicity.Based on the own results and literature data we reported earlier, it can be confirmed that the in vitro cytotoxicity of ruthenium(II) complexes increases with an increase in the size of the arene ligand.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call